|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM333356071 |
| 003 |
DE-627 |
| 005 |
20250302165853.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108879
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1110.xml
|
| 035 |
|
|
|a (DE-627)NLM333356071
|
| 035 |
|
|
|a (NLM)34798239
|
| 035 |
|
|
|a (PII)S1521-6616(21)00216-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Khan, Hasnat
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Role of NRF2 and Sirtuin activators in COVID-19
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.12.2021
|
| 500 |
|
|
|a Date Revised 28.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021. Published by Elsevier Inc.
|
| 520 |
|
|
|a COVID-19 is a pandemic requiring immediate solution for treatment because of its complex pathophysiology. Exploration of novel targets and thus treatment will be life savers which is the need of the hour. 2 host factors- TMPRSS2 and ACE2 are responsible for the way the virus will enter and replicate in the host. Also NRF2 is an important protein responsible for its anti-inflammatory role by multiple mechanisms of action like inhibition of NF-kB, suppression of pro-inflammatory genes, etc. NRF2 is deacetylated by Sirtuins and therefore both have a direct association. Absence of SIRT indicates inhibition of NRF2 expression and thus no anti-oxidative and anti-inflammatory protection for the cell. Therefore, we propose that NRF2 activators and/or SIRT activators can be evaluated to check their efficacy in ameliorating the symptoms of COVID-19
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a ACE2
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a NRF2
|
| 650 |
|
4 |
|a SIRT
|
| 650 |
|
4 |
|a SIRT activators
|
| 650 |
|
4 |
|a TMPRSS2
|
| 650 |
|
7 |
|a NF-E2-Related Factor 2
|2 NLM
|
| 650 |
|
7 |
|a NFE2L2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Angiotensin-Converting Enzyme 2
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.17.23
|2 NLM
|
| 650 |
|
7 |
|a Serine Endopeptidases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
| 650 |
|
7 |
|a TMPRSS2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
| 650 |
|
7 |
|a Sirtuins
|2 NLM
|
| 650 |
|
7 |
|a EC 3.5.1.-
|2 NLM
|
| 700 |
1 |
|
|a Patel, Shivangi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Majumdar, Anuradha
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 233(2021) vom: 15. Dez., Seite 108879
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:233
|g year:2021
|g day:15
|g month:12
|g pages:108879
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108879
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 233
|j 2021
|b 15
|c 12
|h 108879
|